ADVERTISEMENT

Agro-Chem, Specialty Chemical, Midcaps Q2 Preview - Top-Line Healthy; Cost Pressures Rising: Axis Securities

Agro-Chem, Specialty Chemical, Midcaps Q2 Preview - Top-Line Healthy; Cost Pressures Rising: Axis Securities

Stock market movements shown on an electronic display in Japan. (Photographer: Kiyoshi Ota/Bloomberg)
Stock market movements shown on an electronic display in Japan. (Photographer: Kiyoshi Ota/Bloomberg)

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Axis Securities Report

  • We expect agrochemical companies under our coverage to deliver a ~13% YoY revenue growth in Q2 FY22 due to-

  1. strong growth momentum in custom synthesis and manufacturing segment for PI Industries Ltd.;

  2. erratic monsoon to impact the herbicide and fungicide categories,

  3. price hike taken across categories to cover rising raw material costs.

  • The specialty chemicals sector continues to be in a sweet spot owing to robust domestic demand, rising import substitution opportunities, strong growth in exports, growing costs within China due to environment related issues and the government’s proactive support under the ‘Make in India’ initiative.

  • In our midcap universe APL Apollo Tubes Ltd. is likely to report revenue growth on account of a 15% sequential increase in volumes on account of easing Covid-19 led restrictions.

Click on the attachment to read the full report:

Axis Securities Agro-Chem, Specialty Chemicals, Mid-Caps-Q2FY22 EarningsPreview.pdf

DISCLAIMER

This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.